60 Degrees Pharmaceuticals (SXTP) announced it has exercised the option in its agreement with Florida State University, FSU, to negotiate an exclusive license to use large-scale purification techniques to extract castanospermine from the seeds of Castanospermum australe. Castanospermum australe grows primarily in the Australian states of Queensland and New South Wales, but also in Florida, Hawaii, and California.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXTP:
- Runway Health Partnership and Multi-Pronged Commercial Strategy Underpin Buy Rating on 60 Degrees Pharmaceuticals
- 60 Degrees Pharmaceuticals target adjusted to $24 at H.C. Wainwright after split
- 60 Degrees Pharmaceuticals Faces Immediate Nasdaq Delisting Appeal
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Here’s Why 60 Degrees Pharmaceuticals Stock (SXTP) Rocketed Today